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Abstract DAN gene was first isolated by differential screening
between rat 3Y1 and v-src-transformed 3Y1 cells and showed a
tumor-suppressive activity toward v-src-transformed 3Y1 cells.
When DAN-transfected neuroblastoma cells were treated with a
tumor promoter phorbol ester, TPA, neurite-like processes
appeared within 2 h whereas no apparent change was observed
in the parent and vector-transfected cells up to 8 h. This suggests
some difference in TPA-receptor, protein kinase C (PKC),
between DAN-transfectants and the control cells. DAN-trans-
fected SH-SY5Y cells showed complete loss in PKCK and a large
decrease in PKCQ. Similar down-regulation in PKCK and PKCQ
was also observed in DAN-transfected Ha-ras-transformed NIH
3T3 cells. The decreased level of PKCK was partially recovered
after treatment with a calpain inhibitor, ZLLH. A 150-kDa
proteolytic product of a calpain-specific substrate, non-erythroid
K-spectrin, was detectable in DAN-transfected SH-SY5Y cells
but not in the parent or vector-transfected control cells. This
suggests that DAN-transfected cells contain activated calpain
which may cause down-regulation of PKC and hence induce the
altered TPA response.
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1. Introduction
Malignant transformation is frequently associated with loss
of expression of tumor-suppressor genes. To identify the can-
didates of tumor-suppressive genes, di¡erential screening be-
tween rat 3Y1 and its v-src-transformed cells was performed
[1]. Among a number of identi¢ed di¡erentially expressed
genes, DAN gene was of much interest since its expression
was completely suppressed in v-src-, v-mos- and SV40-trans-
formed 3Y1 cells [1]. Transfection of DAN into v-src-trans-
formed 3Y1 cells resulted in morphological reversion as well
as loss of tumorigenicity [2]. These results suggested that DAN
possesses a tumor-suppressive activity. Overexpression of
DAN in 3Y1 cells caused retardation of entry into the S phase
in normal cells [3]. Ectopic expression of DAN enhances ret-
inoic acid-induced neuronal di¡erentiation in human neuro-
blastoma cell lines [4]. DAN gene product (DAN) is composed
of 178 amino acid residues with a possible signal peptide at its
amino-terminus and is secreted into culture media although a
substantial amount still remains in the cell [5]. In addition,
DAN has a (HX)n repeat motif and, therefore, an a⁄nity for
Ni2 [6].
Recently, Hsu et al. have identi¢ed a new gene, designated
Gremlin, whose gene product can induce a secondary axis or
hyperdorsalization when it was injected into ventral blasto-
meres of Xenopus embryos [7]. Interestingly, Gremlin contains
a similar structural motif to DAN and Cerberus, which has an
ability to induce an ectopic head in Xenopus embryos [7,8].
Functional analysis has demonstrated that all of these pro-
teins (DAN family) [9] are secreted and can associate with
BMP2 (bone morphogenetic protein) to prevent its signaling
[7]. It was thus suggested that DAN family members can
control diverse processes in cell growth and di¡erentiation.
In the present study, further investigation on the biological
function of DAN was carried out by transfection of DAN
cDNA into human neuroblastoma and mouse ¢broblast cells.
The results showed a remarkable down-regulation of protein
kinase C (PKC) as well as calpain activation in DAN-trans-
fected cells.
2. Materials and methods
2.1. Cell culture
SH-SY5Y neuroblastoma cell line [9] was cultured in RPMI 1640
supplemented with 10% fetal bovine serum and OPI (Sigma). Acti-
vated Ha-ras-transformed NIH 3T3 cells (ras-NIH, clone F25) [10]
were cultured in Dulbecco’s modi¢ed medium supplemented with 5%
calf serum.
2.2. Transfection
Rat DAN cDNA was inserted into eukaryotic expression vectors,
pRc/CMV (Invitrogen) and transfected into SH-SY5Y cells using lipo-
fectin (Gibco-BRL). Transfected cells were selected in the presence of
G418 (400 Wg/ml) and two clones designated D1 and D4 were ob-
tained as described [6]. Rat DAN cDNA was also inserted into the
pMAMneo vector (Clontech) and transfected into ras-NIH cells.
FMD-1 and FMD-6 were G418-selected DAN-expressing clones and
FVE-5 and FVE-8 were the vector-transfected control clones.
2.3. Treatment of transfected cells with Dex and ZLLH
To induce the expression of DAN, the transfected NIH 3T3 cells
were treated with dexamethasone (Dex, 1 WM) or the solvent dimeth-
ylsulfoxide (DMSO, 0.1%) for 2 days. To inhibit the calpain activity,
cells were treated with ZLLH (50 WM) (Peptide Institute, Osaka,
Japan) for 24 h.
2.4. Preparation of cell extract and Western blot analysis
Cells were lysed in 0.5% Nonidet P-40, 20 mM Tris-HCl (pH 7.5),
1 mM EDTA, 1 mM EGTA, 1 mM phenylmethylsulfonyl £uoride
and 50 WM N-acetyl-leucyl-leucyl-norleucinal as described, incubated
at 0‡C for 10 min and centrifuged at 13 000Ug for 10 min. The super-
natant was then electrophoresed through an SDS-polyacrylamide gel
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followed by immunoblot analysis using a⁄nity-puri¢ed anti-rat DAN
polyclonal antibody [3,4], anti-PKC antibody (Amersham), anti-
PKCK, -L, -Q, -N, -O, -S, -W, -a, -V and -j antibodies (Transduction
Laboratories), and anti-150-kDa-non-erythroid K-spectrin (fodrin)
antibody [11], as described previously [12].
3. Results
The expression of DAN is reduced in several human neuro-
blastoma cell lines including SH-SY5Y. DAN gene is mapped
to chromosome 1p36.11-p36.13, which is close to the com-
monly deleted chromosome region in neuroblastomas [10].
To assess the tumor-suppressive activity of DAN against neu-
roblastoma cells, rat DAN cDNA was inserted in a constitu-
tive expression vector, pRc/CMV, and transfected into SH-
SY5Y cells [6]. Several G418-resistant clones were isolated
and the expression of DAN was examined by immunoblot
analysis. DAN was highly expressed in clones D1 and D4
(Fig. 1A). Anti-rat DAN antibody used in the present study
could not recognize endogenous human DAN [6], and hence
we were unable to estimate the increase in the amount of
DAN in transfected cells.
When the transfected cells were treated with a tumor pro-
moter phorbol ester, TPA, a marked increase in neurite for-
mation was observed in DAN- but not in vector-transfected
clones. Within 2 h of the addition of TPA, many neurite-like
processes were formed in D4 cells (Fig. 2C and D), whereas
vector-control cells did not show any morphological change at
this time interval (Fig. 2A and B) or even 12 h after the
addition of TPA (data not shown). The response to TPA in
parent SH-SY5Y cells was similar to that of vector-transfected
cells (data not shown).
The large di¡erence in response to TPA between DAN-
overexpressors and control cells suggested a possible altera-
tion in TPA-receptor, PKC, in DAN-transfected cells. Thus,
in the next step, we analyzed both the types and amounts of
PKC by immunoblot. The results showed a complete loss of
PKCK in two DAN-transfectants (Fig. 1B). The parent and
vector-control cells contained high levels of PKCK. PKCQ,
PKCN, PKCV and PKCa decreased but did not completely
disappear in DAN-transfected D4 cells (Fig. 1D). Notably,
the molecular size of PKCN was reduced in D4 cells, suggest-
ing that the decrease in PKCs was due to increased degrada-
tion. On the other hand, the expression of PKCW and -j was
slightly increased in DAN-transfected cells (Fig. 1D). The ex-
pression of PKCL and PKCS was below the detection level
(data not shown).
It is still unclear whether down-regulation of PKC can be
induced directly by DAN itself. Then, we transfected DAN
gene with an inducible expression vector, pMSG, into ras-
NIH cells. Among the transfectants, FMD1, FMD6 and
FMD7, showed a high expression of DAN after treatment
with dexamethasone (Dex) and a low leaked expression with-
out treatment (Fig. 3A, data not shown). Another vector-
transfected clone, FVE-5, did not express a detectable level
of DAN irrespective of treatment with Dex. The level of
PKCK correlated inversely with the expression of DAN, i.e.
PKCK decreased after induction of DAN expression by Dex
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Fig. 1. Expression of DAN, PKCK and fodrin in DAN-transfected SH-SY5Y neuroblastoma cells. Cell extracts of parent SH-SY5Y cells (SY),
vector-transfected control clone (V) and two DAN-transfected clones (D4 and D1) were analyzed by immunoblot using anti-DAN (A), anti-
PKCK (B), anti-150-kDa fodrin (C) and anti-PKC subtype-speci¢c antibodies (D). Anti-fodrin antibody used in C was 150-kDa-form-speci¢c
and therefore the 240-kDa precursor form was not seen.
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(Fig. 3B). A slightly higher mobility of PKCK in FMD1 com-
pared with that in FVE5 suggested that truncating degrada-
tion of PKCK might occur in the DAN-transfectant. Similar
di¡erences in the level and molecular size of PKCK were also
observed between other vector-transfected FVE1 cells and
DAN-transfected FMD7 cell (Fig. 3C). The level of PKCQ,
PKCa and PKCj also decreased in FMD7 cells compared
to those in FVE1 cells. The expression of PKCL, PKCN and
PKCS was undetectable in these cells (data not shown).
The decrease in both the protein amount and molecular size
of multiple subtypes of PKC suggested that these changes
were induced by enhanced degradation rather than reduced
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Fig. 2. Phase morphology of DAN-transfected SH-SY5Y cells before or after treatment with TPA. Shown are phase micrographs of vector-
transfected SH-SY5Y cells (A and B) and DAN-transfected D4 cells (C and D). A and C show the cells without any treatment, and B and D
show cells after treatment with 100 nM TPA for 2 h. Original magni¢cation, U100.
Fig. 3. Expression of DAN and PKCK in DAN-transfected ras-NIH cells. A and B: DAN-transfected ras-NIH (FMD1) and the vector-control
clone (FVE5) were treated with (+) or without (3) Dex at a concentration of 1 WM for 2 days. The cell extract was analyzed by immunoblot
using anti-DAN (A) and anti-PKCK antibodies (B). C: Vector-transfected FVE1 and DAN-transfected FMD7 were treated with Dex for 2 days
and the cell extract was analyzed by immunoblot using anti-PKC subtype-speci¢c antibodies. D: FMD6 was treated with a calpain inhibitor,
ZLLH, at a concentration of 50 WM for 24 h. For control, the cells were treated with the solvent DMSO (DM). Results of immunoblot using
anti-PKCK are shown. Cell extract of a vector-transfected FVE8 without any treatment was also examined.
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synthesis. PKC can be degraded by a calcium-dependent neu-
tral proteinase, calpain [11]. If the decrease in PKC is caused
by calpain, the level of PKC might increase by a calpain
inhibitor. FMD6, another DAN-transfected ras-NIH clone,
was treated with a calpain inhibitor, ZLLH [12], for 24 h
and PKC was examined by immunoblot. FMD6 showed a
similar decrease in PKCK without Dex treatment compared
with a vector control, FVE8, probably due to a leaked ex-
pression of DAN (Fig. 3D). Treatment with ZLLH signi¢-
cantly increased the level of PKCK although the increased
level was still lower than that in untreated FVE8. These re-
sults suggest that calpain activity is enhanced in DAN-trans-
fected cells. The intracellular activity of calpain can be esti-
mated by investigating the degradation of the speci¢c
substrate, non-erythroid K-spectrin (fodrin) [13]. Immunoblot
analysis showed the presence of a 150-kDa degradation prod-
uct of fodrin only in DAN-transfected clones but not in the
parent and vector-control cells (Fig. 1C). This implies that
calpain is activated in DAN-transfectants.
4. Discussion
DAN gene product has a tumor-suppressive activity in v-
src-transformed 3Y1 cells [2]. On the other hand, other mem-
bers of DAN family possess di¡erent biological activities, i.e.
Gremlin induces a secondary axis in Xenopus embryo [8] and
Cerberus promotes the formation of head structures such as
cement gland, olfactory placodes, eyes and forebrain [7]. All
three members are secreted and bind BMP2 [8]. Thus, we
postulated that DAN family was probably involved in con-
trolling cell growth and di¡erentiation by a¡ecting signaling
of TGFL family [8]. However, the precise mechanism of ac-
tion of DAN family remains to be con¢rmed.
In the present study, we found marked di¡erences in TPA-
induced neurite formation between DAN-transfected and con-
trol cells (Fig. 2). This suggested that certain changes were
induced in the receptor, PKC, or its downstream pathway.
Immunoblot analysis showed a complete loss of PKCK irre-
spective of the expression level of DAN (Fig. 1B). Some of
other PKC subtypes also decreased not only in DAN-trans-
fected neuroblastoma cells but also in DAN-transfected ras-
NIH cells (Figs. 1D and 3C). Consequently, down-regulation
of PKC can be one of the intrinsic changes caused by DAN.
A dramatic induction of neurite formation after treatment
with TPA was observed only in DAN-transfected SH-SY5Y
cells despite the undetectable expression level of PKCK. A
possible explanation is that the loss of PKCK could result in
binding of TPA to another PKC subtype, which e¡ectively
induces neurite formation. It is important to identify the
PKC subtype mainly involved in neuronal di¡erentiation. A
recent report has shown that PKCK, -Q, -O and -a are down-
regulated after treatment with TPA in lymphokine-activated
killer cells [16]. Thus, PKCO, which was not reduced in DAN-
transfected cells, might be a possible candidate. The implica-
tion of PKCO in neurite outgrowth in SH-SY5Y cells has also
been suggested by Fagerstrom et al. [17].
It is conceivable that the decrease in PKCs was not induced
by a reduced synthesis but by enhanced degradation since
down-regulation was observed not only in PKCK but also
in other PKC subtypes in DAN-transfected cells (Figs. 1D
and 3C). It is well documented that PKC is degraded by a
Ca2-activated neutral cysteine proteinase, calpain [14,15].
The involvement of calpain in PKC regulation was suggested
by our results that the reduced expression level of PKCK in
DAN-transfected cells was partly recovered by treatment with
a calpain inhibitor, ZLLH (Fig. 3D). The appearance of a
150-kDa degradation product of fodrin strongly suggests
that calpain was activated in DAN-transfected cells.
How calpain was activated in DAN-transfected cells re-
mains unknown at present. Calpain activity is regulated by
Ca2, dissociation of a small subunit, a speci¢c inhibitor,
calpastatin [18] and calpain activator proteins [19^21]. It is
also possible that the activation of calpain was not the cause
but the result of activation of PKCs. Further investigation is
necessary to elucidate the mechanism of calpain activation
and PKC down-regulation in DAN-transfected cells as well
as their possible involvement in neuronal di¡erentiation and
malignant transformation.
Acknowledgements: This work was partly supported by a Grant-in-
Aid for Scienti¢c Research (C) from the Ministry of Education, Sci-
ence, Sports and Culture of Japan and also by a Grant-in-Aid for a
New Comprehensive 10-Year Strategy for Cancer Control from the
Ministry of Health and Welfare, Japan.
References
[1] Ozaki, T. and Sakiyama, S. (1993) Proc. Natl. Acad. Sci. USA
90, 2593^2597.
[2] Ozaki, T. and Sakiyama, S. (1994) Cancer Res. 54, 646^648.
[3] Ozaki, T., Nakamura, Y., Enomoto, H., Hirose, M. and Sakiya-
ma, S. (1995) Cancer Res. 55, 895^900.
[4] Nakamura, Y., Ozaki, T., Nakagawara, A. and Sakiyama, S.
(1997) Eur. J. Cancer 33, 1986^1990.
[5] Kondo, K., Ozaki, T., Nakamura, Y. and Sakiyama, S. (1995)
Biochem. Biophys. Res. Commun. 216, 209^215.
[6] Nakamura, Y., Ozaki, T., Ichimiya, S., Nakagawara, A. and
Sakiyama, S. (1998) Biochem. Biophys. Res. Commun. 243,
722^726.
[7] Bouwmeester, T., Kim, S., Sasai, Y., Lu, B. and De Robertis,
E.M. (1996) Curr. Opin. Genet. Dev. 3, 641^647.
[8] Hsu, D.R., Economides, A.N., Wang, X., Eimon, P.M. and Har-
land, R.M. (1998) Mol. Cell 1, 673^683.
[9] Ciccarone, V., Spengler, B.A., Meyers, M.B., Biedler, J.L. and
Ross, R.A. (1989) Cancer Res. 49, 219^225.
[10] Sekiya, T., Fushimi, M., Hori, H., Hirohashi, S., Nishimura, S. and
Sugimura, T. (1984) Proc. Natl. Acad. Sci. USA 81, 4771^4775.
[11] Saido, T.C., Yokota, M., Nagao, S., Yamaura, I., Tani, E., Tsu-
chiya, T., Suzuki, K. and Kawashima, S. (1993) J. Biol. Chem.
268, 25239^25243.
[12] Hiwasa, T., Ma, J., Ike, Y., Katunuma, N. and Sakiyama, S.
(1995) Cell Biochem. Funct. 13, 293^296.
[13] Enomoto, H., Ozaki, T., Takahashi, E., Nomura, N., Tabata, S.,
Yakahashi, H., Ohnuma, N., Tanabe, M., Iwai, J., Yoshida, H.,
Matsunaga, T. and Sakiyama, S. (1994) Oncogene 9, 2785^2791.
[14] Kishimoto, A., Mikawa, K., Hashimoto, K., Yasuda, I., Tanaka,
S., Tominaga, M., Kuroda, T. and Nishizuka, Y. (1989) J. Biol.
Chem. 264, 4088^4092.
[15] Tsubuki, S., Saito, Y., Tomioka, M., Ito, H. and Kawashima, S.
(1996) J. Biochem. 119, 572^576.
[16] Ohmi, Y., Ohta, A., Sasakuma, Y., Sato, N., Yahata, T., Santa,
K., Habu, S. and Nishimura, T. (1997) Biochem. Biophys. Res.
Commun. 235, 461^464.
[17] Fagerstrom, S., Pahlman, S., Gestblom, S. and Nanberg, E.
(1996) Cell Growth Di¡er. 7, 775^785.
[18] Saido, T.C., Sorimachi, H. and Suzuki, K. (1994) FASEB J. 8,
814^822.
[19] Yamaguchi, M. and Nishina, N. (1995) Mol. Cell. Biochem. 148,
67^72.
[20] Melloni, E., Michetti, M., Salamino, F. and Pontremoli, S. (1998)
J. Biol. Chem. 273, 12827^12831.
[21] Dale, L., Howes, G., Price, B.M. and Simth, J.C. (1992) Develop-
ment 115, 573^585.
FEBS 21165 30-11-98
T. Hiwasa et al./FEBS Letters 440 (1998) 25^2828
